Advanced in Metastatic Brain Tumor

Olivier Michielin

Lausanne Branch, 
Lausanne, VD, CH 
Advanced in Metastatic Brain Tumor
Lausanne Branch, 
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Olivier Michielin practices in Lausanne, Switzerland. Mr. Michielin is rated as an Advanced expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Melanoma, Metastatic Brain Tumor, Large-Cell Immunoblastic Lymphoma, and Metastatic Uveal Melanoma.

His clinical research consists of co-authoring 236 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Lausanne Branch, Lausanne, VD, Switzerland
Other Locations
Ludwig Cancer Research Lausanne Branch, Lausanne, VD, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Study Drug: MVX-ONCO-1 Vaccine
Study Phase: Not Applicable
An Interventional Phase II Study to Analyze the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
An Interventional Phase II Study to Analyze the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant
Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A/Mart-1 Analog (ELA), NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant
Enrollment Status: Completed
Publish Date: June 18, 2020
Intervention Type: Biological
Study Phase: Phase 1
View 2 Less Clinical Trials

236 Total Publications

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.
Journal: Swiss medical weekly
Published: August 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Michielin's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile